{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.11","upperLimit":"19.29","value":"11.79"},{"comment":"Upper limit of confidence interval could not be estimated due to an insufficient number of events.","groupId":"OG001","lowerLimit":"16.85","upperLimit":"NA","value":"31.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"OS was defined as the time between the date of administration of the first dose of the study drug and the date of death due to any cause. Participants who were alive at cut-off were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory PTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG000","title":"PTCL: E7777 9 mcg/kg/Day"},{"description":"Participants with CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG001","title":"CTCL: E7777 9 mcg/kg/Day"},{"description":"Participant with extranodal NK/T-cell lymphoma received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG002","title":"Other: E7777 9 mcg/kg/Day"}],"paramType":"MEDIAN","populationDescription":"The FAS was defined as a group of participants who received at least 1 dose of the study drug.","reportingStatus":"POSTED","timeFrame":"From date of administration of the first dose of the study drug until the date of death due to any cause up to approximately 3 years 1 month","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}